Cannabinoid signaling and risk in Huntington's disease

Area of Science:

• Neuroscience
• Computational Biology
• Neurodegenerative Diseases

Background:

• Huntington's disease (HD) is characterized by altered endocannabinoid (eCB) signaling and loss of cannabinoid receptors (CB1Rs).
• The specific role of eCB signaling in HD circuit dysfunction remains unclear.

Purpose of the Study:

• To investigate the contribution of eCB signaling to circuit-level alterations in Huntington's disease.
• To model the homeostatic functions of eCB signaling and its dysregulation in HD.

Main Methods:

• Development of a computational model simulating spiking neurons, synapses, and eCB signaling.
• Analysis of eCB signaling's role in regulating glutamate levels.
• Modeling the impact of metabolic risk factors like excess glutamate and altered synaptic plasticity on eCB signaling and receptor expression.

Main Results:

• eCB signaling acts as a homeostatic mechanism to minimize excess glutamate.
• Metabolic risk, indicated by elevated glutamate, increases with cortico-striatal long-term depression (LTD) and/or heightened activity.
• The model replicates the progressive loss of cannabinoid receptors on inhibitory terminals, correlating with the excitatory/inhibitory ratio.

Conclusions:

• eCB signaling plays a crucial homeostatic role in neuronal circuits.
• Dysregulation of eCB signaling, particularly the loss of CB1Rs, contributes to the progression of Huntington's disease.
• Computational modeling provides insights into the complex interplay between metabolic risk, synaptic plasticity, and receptor dynamics in HD.